Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abemaciclib works in treating patients with triple
negative breast cancer that can be removed by surgery (resectable) and does not respond to
treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth.